Freedman Financial Associates’s Alexion Pharmaceuticals ALXN Stock Holding History

Freedman Financial Associates’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-207	Closed	-$38K	–	496
2021 Q2	$38K	Hold	207	–	–	0.03%	224
2021 Q1	$32K	Hold	207	–	–	0.03%	253
2020 Q4	$32K	Buy	+207	New	+$26.6K	0.03%	242

Other funds holding ALXN

Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return

Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Freedman Financial Associates's ALXN Position: Q3 2021 in Review

Freedman Financial Associates sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 207 shares — an estimated $38K sold.

Freedman Financial Associates first reported a position in ALXN in Q4 2020 and held it in 3 quarters. The position peaked at $38K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Freedman Financial Associates reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Freedman Financial Associates sold 207 Alexion Pharmaceuticals shares in Q3 2021, an estimated $38K.
Freedman Financial Associates first reported a position in Alexion Pharmaceuticals in Q4 2020 and held it in 3 quarters.
Freedman Financial Associates's Alexion Pharmaceuticals position peaked at $38K in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Freedman Financial Associates's 13F filing for Q3 2021, filed 8 Oct 2021.